Showing results (11-20 of 30) with videos related to
Sort By:
Pageof 3
Personalized Medicine|February 4, 2022
Alignment of health plan coverage policies for somatic multigene panel testing with clinical guidelines in select solid tumorsWilliam B Wong, Daniele Anina, Chia-Wei Lin, et al.Cancer Research Communications|December 1, 2025
Real-World Clinical Oncology Outcomes Associated With the Accelerated Approval PathwayTu My To, Stacey Kowal, James D Chambers, et al.American Journal of Ophthalmology|May 14, 2016
Predictors, Resource Utilization, and Short-term Costs of Laser Trabeculoplasty Versus Medication Management in Open-Angle GlaucomaNeil M Schultz, William B Wong, Anne L Coleman, et al.Journal of Oncology Practice|September 12, 2019
Real-World Clinical and Economic Outcomes and the Role of Bevacizumab in Patients With Non-Small-Cell Lung Cancer With Liver MetastasesWilliam B Wong, Ning Wu, Erru Yang, et al.JCO Oncology Practice|May 27, 2021
Association Between Medicare's National Coverage Determination and Utilization of Next-Generation SequencingDaniel M Sheinson, William B Wong, Carlos Flores, et al.Journal of the National Comprehensive Cancer Network : JNCCN|May 11, 2022
Associations Between Medicaid Insurance, Biomarker Testing, and Outcomes in Patients With Advanced NSCLCCary P Gross, Craig S Meyer, Sarika Ogale, et al.Journal of Managed Care & Specialty Pharmacy|December 16, 2021
Real-world adherence and persistence with anaplastic lymphoma kinase inhibitors in non-small cell lung cancerApar Kishor Ganti, Chia-Wei Lin, Erru Yang, et al.The Oncologist|July 7, 2020
Value of Precision Medicine in Advanced Non-Small Cell Lung Cancer: Real-World Outcomes Associated with the Use of Companion DiagnosticsAni John, Roma A Shah, William B Wong, et al.Journal of Managed Care & Specialty Pharmacy|October 29, 2024
A descriptive survey of patient experiences and access to specialty medicines with alternative funding programsWilliam B Wong, Irina Yermilov, Hannah Dalglish, et al.Pharmacoeconomics|May 8, 2022
Modeling the Ex Ante Clinical Real Option Value in an Innovative Therapeutic Area: ALK-Positive Non-Small-Cell Lung CancerWoojung Lee, William B Wong, Stacey Kowal, et al.Pageof 3